JP5537033B2 - 無痛覚 - Google Patents
無痛覚 Download PDFInfo
- Publication number
- JP5537033B2 JP5537033B2 JP2008546592A JP2008546592A JP5537033B2 JP 5537033 B2 JP5537033 B2 JP 5537033B2 JP 2008546592 A JP2008546592 A JP 2008546592A JP 2008546592 A JP2008546592 A JP 2008546592A JP 5537033 B2 JP5537033 B2 JP 5537033B2
- Authority
- JP
- Japan
- Prior art keywords
- glycine
- receptor
- effect
- compounds
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 claims description 160
- 208000002193 Pain Diseases 0.000 claims description 35
- 230000036407 pain Effects 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- QNJVELOLCDKQBN-UHFFFAOYSA-N 4-bromo-2,6-di(propan-2-yl)phenol Chemical compound CC(C)C1=CC(Br)=CC(C(C)C)=C1O QNJVELOLCDKQBN-UHFFFAOYSA-N 0.000 claims description 14
- JMJHJCFWTNRPEI-UHFFFAOYSA-N 4-iodopropofol Chemical compound CC(C)C1=CC(I)=CC(C(C)C)=C1O JMJHJCFWTNRPEI-UHFFFAOYSA-N 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 239000000460 chlorine Substances 0.000 claims description 12
- ZRTAKZQCHCQFAB-UHFFFAOYSA-N 4-chloro-2,6-di(propan-2-yl)phenol Chemical compound CC(C)C1=CC(Cl)=CC(C(C)C)=C1O ZRTAKZQCHCQFAB-UHFFFAOYSA-N 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 208000000094 Chronic Pain Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- GSTILJJZVXEDIR-UHFFFAOYSA-N 4-chloro-3,5-di(propan-2-yl)phenol Chemical compound CC(C)C1=CC(O)=CC(C(C)C)=C1Cl GSTILJJZVXEDIR-UHFFFAOYSA-N 0.000 claims description 2
- BAHYFNRLSGHTRP-UHFFFAOYSA-N 4-fluoro-2,6-di(propan-2-yl)phenol Chemical compound CC(C)C1=CC(F)=CC(C(C)C)=C1O BAHYFNRLSGHTRP-UHFFFAOYSA-N 0.000 claims description 2
- VJUMNSVYUGRAEN-UHFFFAOYSA-N 4-fluoro-3,5-di(propan-2-yl)phenol Chemical compound CC(C)C1=CC(O)=CC(C(C)C)=C1F VJUMNSVYUGRAEN-UHFFFAOYSA-N 0.000 claims description 2
- ZUAUTJASOBMZKX-UHFFFAOYSA-N 4-iodo-3,5-di(propan-2-yl)phenol Chemical compound CC(C)C1=CC(O)=CC(C(C)C)=C1I ZUAUTJASOBMZKX-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 216
- 239000004471 Glycine Substances 0.000 description 109
- 102000011714 Glycine Receptors Human genes 0.000 description 106
- 108010076533 Glycine Receptors Proteins 0.000 description 106
- 230000000694 effects Effects 0.000 description 98
- 102000005962 receptors Human genes 0.000 description 62
- 108020003175 receptors Proteins 0.000 description 62
- 230000006690 co-activation Effects 0.000 description 58
- 230000004044 response Effects 0.000 description 51
- 238000002474 experimental method Methods 0.000 description 43
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 40
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 37
- 150000002989 phenols Chemical class 0.000 description 37
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 35
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 33
- 229960004134 propofol Drugs 0.000 description 26
- 230000009182 swimming Effects 0.000 description 23
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 20
- 238000010586 diagram Methods 0.000 description 19
- TUAMRELNJMMDMT-UHFFFAOYSA-N 3,5-xylenol Chemical compound CC1=CC(C)=CC(O)=C1 TUAMRELNJMMDMT-UHFFFAOYSA-N 0.000 description 18
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 18
- 241001279009 Strychnos toxifera Species 0.000 description 17
- 230000004913 activation Effects 0.000 description 17
- 239000000556 agonist Substances 0.000 description 17
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 17
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 229960005453 strychnine Drugs 0.000 description 17
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- 229940035676 analgesics Drugs 0.000 description 15
- 239000000730 antalgic agent Substances 0.000 description 15
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 15
- 230000000202 analgesic effect Effects 0.000 description 14
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 14
- 108010052164 Sodium Channels Proteins 0.000 description 13
- 102000018674 Sodium Channels Human genes 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 230000006399 behavior Effects 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- 210000003169 central nervous system Anatomy 0.000 description 10
- 210000000278 spinal cord Anatomy 0.000 description 10
- 241000269370 Xenopus <genus> Species 0.000 description 9
- 230000003444 anaesthetic effect Effects 0.000 description 9
- 230000003252 repetitive effect Effects 0.000 description 9
- NXXYKOUNUYWIHA-UHFFFAOYSA-N 2,6-Dimethylphenol Chemical compound CC1=CC=CC(C)=C1O NXXYKOUNUYWIHA-UHFFFAOYSA-N 0.000 description 8
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 8
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 8
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical class O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 108091006146 Channels Proteins 0.000 description 7
- 102000005915 GABA Receptors Human genes 0.000 description 7
- 108010005551 GABA Receptors Proteins 0.000 description 7
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 7
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000000575 glycinergic effect Effects 0.000 description 7
- 102000055647 human CSF2RB Human genes 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 230000005062 synaptic transmission Effects 0.000 description 6
- 230000027682 synaptic transmission, glycinergic Effects 0.000 description 6
- HKJKCPKPSSVUHY-GRTNUQQKSA-M (6r)-6-[(5s)-6,6-dimethyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl]-6h-furo[3,4-g][1,3]benzodioxol-8-one;iodide Chemical compound [I-].O([C@H]1[C@@H]2C3=CC=4OCOC=4C=C3CC[N+]2(C)C)C(=O)C2=C1C=CC1=C2OCO1 HKJKCPKPSSVUHY-GRTNUQQKSA-M 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000003281 allosteric effect Effects 0.000 description 5
- 229940035674 anesthetics Drugs 0.000 description 5
- 239000003193 general anesthetic agent Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000000273 spinal nerve root Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000003371 gabaergic effect Effects 0.000 description 4
- 230000026030 halogenation Effects 0.000 description 4
- 238000005658 halogenation reaction Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000007913 intrathecal administration Methods 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000003483 4 aminobutyric acid A receptor stimulating agent Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102000011045 Chloride Channels Human genes 0.000 description 3
- 108010062745 Chloride Channels Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000009205 glycinergic inhibition Effects 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000001153 interneuron Anatomy 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 230000001242 postsynaptic effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 230000007428 synaptic transmission, GABAergic Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000017453 Glycine receptor alpha Human genes 0.000 description 2
- 108050005643 Glycine receptor alpha Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003502 anti-nociceptive effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002332 glycine derivatives Chemical class 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000009539 inhibitory neurotransmission Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000012439 solid excipient Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- YYVIACQIJLPZFT-UHFFFAOYSA-N 4-bromo-3,5-di(propan-2-yl)phenol Chemical compound CC(C)C1=CC(O)=CC(C(C)C)=C1Br YYVIACQIJLPZFT-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 101710195183 Alpha-bungarotoxin Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940122391 Glycine receptor agonist Drugs 0.000 description 1
- 102000013704 Glycine receptor beta Human genes 0.000 description 1
- 108050003545 Glycine receptor beta Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001661355 Synapsis Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000008856 allosteric binding Effects 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229940015508 gabapentin 100 mg Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 239000002431 glycine receptor agonist Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 230000008062 neuronal firing Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 229940125794 sodium channel blocker Drugs 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- -1 transdermal patches Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75155905P | 2005-12-19 | 2005-12-19 | |
| US60/751,559 | 2005-12-19 | ||
| US79627006P | 2006-04-27 | 2006-04-27 | |
| US60/796,270 | 2006-04-27 | ||
| PCT/GB2006/004762 WO2007071967A2 (en) | 2005-12-19 | 2006-12-19 | Substituted phenol derivatives as analgesics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009520010A JP2009520010A (ja) | 2009-05-21 |
| JP2009520010A5 JP2009520010A5 (https=) | 2010-02-12 |
| JP5537033B2 true JP5537033B2 (ja) | 2014-07-02 |
Family
ID=37909696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008546592A Expired - Fee Related JP5537033B2 (ja) | 2005-12-19 | 2006-12-19 | 無痛覚 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20070142477A1 (https=) |
| EP (1) | EP1965780B1 (https=) |
| JP (1) | JP5537033B2 (https=) |
| AU (1) | AU2006328198B2 (https=) |
| CA (1) | CA2632561C (https=) |
| WO (1) | WO2007071967A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1965780B1 (en) * | 2005-12-19 | 2017-03-08 | The University Of Liverpool | Propofol derivatives as analgesics |
| BRPI0811220A2 (pt) | 2007-05-09 | 2014-10-29 | Pharmacofore Inc | Compostos terapêuticos |
| MX2009012125A (es) * | 2007-05-09 | 2010-02-18 | Pharmacofore Inc | Compuestos terapeuticos. |
| GB0822486D0 (en) * | 2008-12-10 | 2009-01-14 | Univ Liverpool | Compounds for use in the treatment of pain |
| US20130005718A1 (en) * | 2009-08-11 | 2013-01-03 | Tibbs Gareth R | Compositions and methods of treating chronic pain by administering propofol derivatives |
| CN103896743B (zh) * | 2012-12-28 | 2017-04-05 | 四川海思科制药有限公司 | 一种2，6‑二异丙基‑4‑氟苯酚的制备方法 |
| GB201322905D0 (en) | 2013-12-23 | 2014-02-12 | Univ Liverpool | Pharmacologically active compounds |
| US10449198B2 (en) | 2016-07-01 | 2019-10-22 | The University Of Liverpool | Method for treating pain |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2087019B1 (es) * | 1994-02-08 | 1997-03-16 | Bobel246 S L | Uso de derivados de fenoles 2,4-disubstituidos como inhibidores de la 5-lipoxigenasa. |
| US6518315B1 (en) * | 1997-10-21 | 2003-02-11 | The University Of Sydney | Medicinal uses of phenylaikanols and derivatives |
| US6342533B1 (en) * | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
| WO2000054588A1 (en) * | 1999-03-15 | 2000-09-21 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| MXPA03004862A (es) * | 2000-12-04 | 2005-02-14 | Hoffmann La Roche | Derivados de feniletenilo o feniletinilo como antagonistas del receptor de glutamato. |
| JP4334229B2 (ja) * | 2001-03-20 | 2009-09-30 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤 |
| US20040038874A1 (en) * | 2002-08-22 | 2004-02-26 | Osemwota Omoigui | Method of treatment of persistent pain |
| US20040147581A1 (en) * | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
| US7261882B2 (en) * | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| WO2005033279A2 (en) * | 2003-09-29 | 2005-04-14 | University Of Virginia Patent Foundation | Discovery of novel soluble crystalline anesthetics |
| DE102005033496A1 (de) * | 2005-07-19 | 2007-01-25 | Bayer Healthcare Ag | Desinfektionsmittel |
| EP1965780B1 (en) * | 2005-12-19 | 2017-03-08 | The University Of Liverpool | Propofol derivatives as analgesics |
-
2006
- 2006-12-19 EP EP06842182.5A patent/EP1965780B1/en not_active Not-in-force
- 2006-12-19 AU AU2006328198A patent/AU2006328198B2/en not_active Ceased
- 2006-12-19 JP JP2008546592A patent/JP5537033B2/ja not_active Expired - Fee Related
- 2006-12-19 CA CA2632561A patent/CA2632561C/en not_active Expired - Fee Related
- 2006-12-19 US US11/612,623 patent/US20070142477A1/en not_active Abandoned
- 2006-12-19 WO PCT/GB2006/004762 patent/WO2007071967A2/en not_active Ceased
-
2015
- 2015-11-24 US US14/951,003 patent/US20160095823A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006328198B2 (en) | 2013-07-18 |
| AU2006328198A1 (en) | 2007-06-28 |
| EP1965780B1 (en) | 2017-03-08 |
| US20070142477A1 (en) | 2007-06-21 |
| US20160095823A1 (en) | 2016-04-07 |
| CA2632561C (en) | 2015-01-27 |
| CA2632561A1 (en) | 2007-06-28 |
| EP1965780A2 (en) | 2008-09-10 |
| JP2009520010A (ja) | 2009-05-21 |
| WO2007071967A3 (en) | 2007-10-11 |
| WO2007071967A2 (en) | 2007-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160095823A1 (en) | Methods of using propofol derivatives for analgesia | |
| Merlos et al. | Pharmacological modulation of the sigma 1 receptor and the treatment of pain | |
| Massa et al. | Vanilloid receptor (TRPV1)-deficient mice show increased susceptibility to dinitrobenzene sulfonic acid induced colitis | |
| US8338457B2 (en) | Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist | |
| McCleane | Pharmacological management of neuropathic pain | |
| Brown et al. | Studies on the acute inflammatory response. I. Involvement of the central nervous system in certain models of inflammation | |
| Lecci et al. | Involvement of 5-hydroxytryptamine1A receptors in the modulation of micturition reflexes in the anesthetized rat. | |
| US20190358175A1 (en) | Compositions and methods of treating chronic pain by administering propofol derivatives | |
| US5474990A (en) | Barbiturates as safening agents in conjunction with NMDA antagonists | |
| Hirate et al. | Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors | |
| WO2002100248A2 (en) | Compositions and methods relating to glucose metabolism, weight control, and food intake | |
| BR112014009322B1 (pt) | Uso de um inibidor de catecol-o-metiltransferase (comt) | |
| US6353024B1 (en) | Method for preventing and treating arthritis, osteo-traumatic pain, and neuralgias with trimebutine | |
| Leiva et al. | Pharmacological and electrophysiological characterization of novel NMDA receptor antagonists | |
| US20110280807A1 (en) | Methods and Models for Stress-Induced Analgesia | |
| Rossignol et al. | Synergistic effect of combining dual enkephalinase inhibitor PL37 and sumatriptan in a preclinical model of migraine | |
| Orser et al. | Mechanisms of general anesthesia | |
| Yu et al. | The role of intracellular sodium (Na+) in the regulation of calcium (Ca2+)-mediated signaling and toxicity | |
| Lynch et al. | Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 KATP channels | |
| US20030119903A1 (en) | Use of trimebutine for treating pain | |
| MXPA02006374A (es) | Combinacion de trimebutina con un opioide analgesico. | |
| Di Stefano | The Residual Impact of Alfaxalone on GABAA Receptors and on the Electrophysiological Properties of Goldfish Pyramidal Neurons | |
| Zhang | Cannabidiol modulation of ion channels and neuronal excitability | |
| Silva-Néto et al. | Headache Medicine | |
| Mongiardo | Zn2+ activates KCNQ1 and KCNN4 K+ channels in T84 human colonic epithelial cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091221 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091221 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120618 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120914 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121218 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130225 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130522 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130529 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130625 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130909 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131209 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140310 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140407 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140425 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5537033 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |